McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease.Neurology. 1984; 34: 939–944.
Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type.Brain Res. 1979; 171: 319–327.
Ingvar DH, Risberg J, Schwartz MS. Evidence of subnormal function of association cortex in presenile dementia.Neurology. 1975; 25: 964–974.
Ichimiya A. Functional and structural brain imagings in dementia.Psychiatry Clin Neurosci. 1998; 52(suppl): S223-S225.
Frackowiak RS, Pozzilli C, Legg NJ, et al. Regional cerebral oxygen supply and utilization in dementia.Brain. 1981; 104: 753–778.
Friedland RP, Brun A, Budinger TF. Pathological and positron emission tomographic correlations in Alzheimer’s disease.Lancet. 1985; 1: 228.
deLeon MJ, George AE, Ferris SH, et al. Positron emission tomography and computed tomography assessments of the aging human brain.J Comput Assist Tomogr. 1984; 8: 88–94.
Foster NL, Chase TN, Mansi L, et al. Cortical abnormalities in Alzheimer’s disease.Ann Neurol. 1984; 16: 649–654.
Benson DF, Kuhl DE, Phelps ME, Cummings JL, Tsai SY. Positron emission tomography in the diagnosis of dementia.Trans Am Neurol Assoc. 1981; 106: 68–71.
Folstein M. The Mini-Mental State Examination. In: Crook T, Ferris SH, Bartus R, eds.Assessment in Geriatric Psychopharmacology. New Canaan: Mark Powley Associates; 1983: 47–51.
American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
Kasa P, Papp H, Kasa P Jr, Torok I. Donepezil dose-dependently inhibits acetylcholinesterase activity in various areas and in the presynaptic cholinergic and the postsynaptic cholinoceptive enzyme positive structures in the human and rat brain.Neuroscience. 2000; 101: 89–100.
Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease: FDG-PET studies in MCI and AD.Eur J Nucl Med Mol Imaging. 2005; 32: 486–510.
Nobili F, Koulibaly M, Vitali P, et al. Brain perfusion follow-up in Alzheimer’s patients during treatment with acetylcholinesterase inhibitors.J Nucl Med. 2002; 43: 983–990.
Brown DR, Hunter R, Wyper DJ, et al. Longitudinal changes in cognitive function and regional cerebral function in Alzheimer’s disease: a SPECT blood flow study.J Psychiatr Res. 1996; 30: 109–126.
Pearlson GD, Harris GJ, Powers RE, et al. Quantitative changes in mesial temporal volume, regional cerebral blood flow cognition in Alzheimer’s disease.Arch Gen Psychiatry. 1992; 49: 402–408.
Harris GJ, Links JM, Pearlson GD, Camargo EE. Cortical circumferential profile of SPECT cerebral perfusion in Alzheimer’s disease.Psychiatr Res. 1991; 40: 167–180.
Furey ML, Pietrini P, Haxby JV. Cholinergic enhancement and increased selectivity of perceptual processing during working memory.Science. 2000; 290: 2315–2319.
Warren S, Hier DB, Pavel D. Visual form of Alzheimer’s disease and its response to anticholinesterase therapy.J Neuroimaging. 1998; 8: 249–252.
Nakano S, Asada T, Matsuda H, et al. Donepezil hydrochloride preserves regional cerebral blood in patients with Alzheimer’s disease.J Nucl Med. 2001; 42: 1441–1445.
Tune L, Tiseo PJ, Ieni J, et al. Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer’s disease: results of a 24-week, double-blind, placebo-controlled study.Am J Geriatr Psychiatry. 2003; 11: 169–177.
Vennerica A, Shanks MF, Staff RT, et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease.Neuroreport. 2002; 13: 83–87.
Ceravolo R, Volterrani D, Tognoni G, et al. Cerebral perfusional effects of cholinesterase inhibitors in Alzheimer’s disease.Clin Neuropharmacol. 2004; 27: 166–170.
Staff RT, Gemmell HG, Shanks MF, et al. Changes in the rCBF images of patients with Alzheimer’s disease receiving donepezil therapy.Nuc Med Communications. 2000; 21: 37–41.